Abstract
Fighting the COVID-19 pandemic requires quick and effective strategies to maximize vaccine uptake. We present two sequential randomized controlled trials (RCTs) that tackle this challenge with behavioral science insights. We deliver text-based nudges to UCLA Health patients one day (first RCT; N=113,229) and eight days (second RCT; N=90,662) after they receive notifications of vaccine eligibility. In the first RCT, text messages designed to make vaccination salient and easy to schedule boost appointment and vaccination rates by 86% and 26%, respectively. Nudges that make patients feel endowed with the vaccine heighten these effects, but addressing vaccine hesitancy via a video-based information intervention does not yield benefits beyond simple text. These results hold across ethnicity and age groups. By contrast, online experiments (N=2,003) soliciting hypothetical responses to the same messages reveal the opposite patterns, underscoring the importance of pilot-testing behavioral nudges in the real world before scaling them up. In the second RCT, we further find that receiving a second reminder boosts appointment and vaccination rates by 52% and 16%, respectively. Our findings suggest that text-based nudges can substantially increase and accelerate COVID-19 vaccinations at almost zero marginal cost, highlighting the promising role of behavioral science in addressing a critical component of the COVID-19 pandemic response.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04800965, NCT04801524
Funding Statement
Funding support for this research was provided by UCLA Health, Anderson School of Management, and Carnegie Mellon University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The RCTs were reviewed and approved by the institutional review board (IRB) at University of California, Los Angeles, which determined that a waiver of informed consent was appropriate. IRB#21-000268. The Amazon Mechanical Turk and Prolific Academic studies were reviewed and approved by the IRB at Carnegie Mellon University, the IRB#: IRBSTUDY2015_00000482.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data analyzed in this paper about randomized controlled trials was provided by UCLA Health and contains protected health information. To protect patient privacy, we cannot publicly post individual-level data on vaccinations. Data about our online experiments and survey are available.
https://osf.io/qn8hr/?view_only=cf7b2bc590054aee8c4a2bae99ef20c5
